对佩罗尼氏病保险覆盖的审查
Nicholas Hricz1, Kevin Schlidt2, Michael Ha1
1Division of Plastic Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
Sexual medicine
|October 25, 2024
概括
对于皮罗尼氏病治疗的保险覆盖有很大的差异. 原酶 clostridium histolyticum 注射和阴茎器件是最被覆盖的,而冲击波疗法很少被覆盖,影响患者获得护理.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 卫生经济学 卫生经济学
背景情况:
- 皮罗尼氏病 (PD) 是一种纤维扩散性疾病,导致阴茎曲,疼痛和勃起功能障碍.
- 治疗选择包括手术,器械,冲击波疗法 (SWT),内伤维拉帕米尔 (IV) 和原酶*Clostridium histolyticum* (CCH) 注射.
研究的目的:
- 调查美国各种皮罗尼氏病治疗模式的保险覆盖范围.
主要方法:
- 基于市场份额和入学率的美国顶级保险政策的横截面分析.
- 通过网络搜索和电话采访确定了政策,并定义了医疗必要性标准.
- 在三年间重新审查政策,以评估变化.
主要成果:
- 在PD治疗的保险覆盖中存在显著的差异.
- 原酶*Clostridium histolyticum* (CCH) 注射 (37/37家公司) 和外部/内部阴茎装置 (18/18家公司) 显示一致覆盖.
- 手术治疗的覆盖率不一致 (57.1%的覆盖率与42.9%的拒绝率),IV仅由两家公司覆盖,SWT普遍被拒绝 (19/19家公司).
结论:
- 对于佩罗尼氏病治疗的保险覆盖范围的差异造成了获得个性化护理的障碍.
- 将保险政策与当前医学文献保持一致对于改善患者获得有效PD治疗的机会至关重要.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
2
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
2
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
2
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
2
Coronary Artery Disease V: Surgical Management
3
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
Nephrotic Syndrome II : Assessment and Medical Management
1
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
1


